Results 271 to 280 of about 165,123 (342)

Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1136-1149, February 2026.
Abstract Aim Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) have been established as effective treatments for type 2 diabetes, offering benefits beyond glycaemic control; however, their associations across multiple health outcomes remain insufficiently assessed.
Dongjin Yeo, Yeona Jo, Jinyoung Jeong, Yi Deun Jeong, Ho Geol Woo, Yejun Son, Sunyoung Kim, Sang Youl Rhee, Dong Keon Yon   +8 more
wiley   +1 more source

Environmental modulators of vascular physiology and inflammation

Experimental Physiology, Volume 111, Issue 2, Page 321-334, 1 February 2026.
Abstract Environmental factors play a crucial role in modulating vascular inflammation, contributing significantly to the development of atherosclerosis and cardiovascular disease. This review synthesizes current evidence on how various environmental exposures influence vascular function and inflammation, with a focus on pollutants such as particulate ...
Anusha N. Seneviratne, Anne Majumdar, Kalpana Surendranath, Mark R. Miller   +3 more
wiley   +1 more source

Neutrophil migration participates in the side effect of recombinant human tissue plasminogen activator. [PDF]

CNS Neurosci Ther
Huang Y, Han Z, Shen T, Zheng Y, Yang Z, Fan J, Wang R, Yan F, Tao Z, Luo Y, Liu P.   +10 more
europepmc   +1 more source

Isoquercetin and Zafirlukast Cooperatively Suppress Tumor Growth and Thromboinflammatory Signaling in a Xenograft Model of Ovarian Cancer

The FASEB Journal, Volume 40, Issue 1, 15 January 2026.
Treatment using either the thiol isomerase inhibitor isoquercetin or zafirlukast lowers tissue factor levels, decreases VEGF, inhibits PD‐L1, and TMEM176B in a xenograft model of ovarian cancer. A combination of the two agents, at threefold lower concentrations than either drug, significantly enhanced the inhibition further, suggesting a dual action of
Justine A. Keovilay, Jason W. Hoskins, Jean‐Pierre Kinet, Thomas C. Lines, Daniel R. Kennedy   +4 more
wiley   +1 more source

Use of recombinant tissue plasminogen activator (rTPA) for treatment of fibrin in the anterior chamber of the horse. [PDF]

Vet Med Sci
Pereira R, Bowen M, Rapezzano G, Redpath A, Pratt S, Hallowell G.   +5 more
europepmc   +1 more source

Early Drainage of Macula-Involving Massive Suprachoroidal Haemorrhage Assisted with Recombinant Tissue Plasminogen Activator May Lead to Better Visual Prognosis. [PDF]

Case Rep Ophthalmol
Khalil M, Schneiders M, Veckeneer M, Depla JA, Feron E, Saidkasimova S.   +5 more
europepmc   +1 more source

Hemi‐Orolingual Angioedema in a Patient With VEXAS Syndrome

eJHaem, Volume 7, Issue 1, February 2026.
Edwin U. Suárez, Teresa Arquero‐Portero, Pilar Llamas‐Sillero   +2 more
wiley   +1 more source

Synergistic effects of neuroprotective drugs with intravenous recombinant tissue plasminogen activator in acute ischemic stroke: A Bayesian network meta-analysis. [PDF]

PLoS One
Dang C, Wang Q, Zhuang Y, Li Q, Lu Y, Xiong Y, Feng L.   +6 more
europepmc   +1 more source

A novel technique for extensive submacular hemorrhage using high-dose tissue plasminogen activator. [PDF]

Indian J Ophthalmol
Chauhan K, Narayanan R.
europepmc   +1 more source

Combined treatment of submacular hemorrhage with low-dose subretinal recombinant tissue plasminogen activator and intravitreal conbercept. [PDF]

BMC Ophthalmol
Ma Y, Rao S, Tan Y, Du H, Sun X.
europepmc   +1 more source